MedTrace Logo

Regulation of Lipoprotein Transport in Metabolic Syndrome

NCT00841217 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2009-02-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether PPAR-delta agonist (GW5015156)had favorable effect on lipoprotein metabolism.

Conditions

Interventions

DRUG

GW501516

2.5mg/day

DRUG

placebo pill

Sponsors & Collaborators

  • National Heart Foundation, Australia

    collaborator OTHER

  • The University of Western Australia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2005-08-31
Completion
2008-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00841217 on ClinicalTrials.gov